What it's for (Indications)
- Clobazam is primarily indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age and older.
- LGS is a severe form of epilepsy characterized by multiple seizure types, intellectual disability, and a characteristic electroencephalogram (EEG) pattern.
- As an adjunctive therapy, clobazam is used in conjunction with other anti-epileptic drugs (AEDs) to help manage the complex and often refractory seizures experienced by individuals with LGS.
- The therapeutic efficacy of clobazam in this population is attributed to its anxiolytic, sedative, and anticonvulsant properties, aiming to reduce seizure frequency and improve overall patient quality of life.
- Its use is carefully considered within a comprehensive treatment plan for this challenging neurological condition.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Clobazam dosage for Lennox-Gastaut Syndrome (LGS) is initiated at a low level and gradually titrated to optimize therapeutic effect while minimizing adverse reactions. For patients weighing 30 kg or more, the recommended starting dose is 10 mg per day, administered in two divided doses (5 mg twice daily). After 7 days, the dose can be increased to 20 mg per day (10 mg twice daily). Further titration may occur up to a maximum of 40 mg per day (20 mg twice daily) as tolerated and based on clinical response. For patients weighing less than 30 kg, the initial dose is 5 mg per day (2.5 mg twice daily). After 7 days, this can be increased to 10 mg per day (5 mg twice daily), with a potential maximum of 20 mg per day (10 mg twice daily). Dose adjustments are crucial for patients with hepatic or severe renal impairment, and for those concomitantly receiving strong CYP2C19 inhibitors, as these factors can significantly alter clobazam metabolism and clearance, potentially increasing exposure and the risk of adverse effects. Abrupt discontinuation should be avoided due to withdrawal risk. |
Safety & Warnings
Common Side Effects
- Clobazam, like other benzodiazepines, can cause a range of adverse effects, primarily related to its central nervous system (CNS) depressant properties.
- Common side effects often include somnolence, sedation, and lethargy, which can significantly impact daily activities, especially during initial therapy or dose escalation.
- Other frequently reported adverse reactions involve ataxia, dizziness, fatigue, and psychomotor slowing.
- Gastrointestinal complaints such as constipation and drooling are also noted.
- In pediatric populations, behavioral changes like aggression, irritability, and paradoxical excitation may occur.
- More serious, albeit less common, adverse effects can include respiratory depression, particularly when co-administered with other CNS depressants such as opioids.
- Severe skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported rarely and require immediate medical attention.
- The potential for physical and psychological dependence, leading to withdrawal symptoms upon abrupt discontinuation, is also a significant concern, necessitating careful monitoring and gradual dose tapering.
Serious Warnings
- Black Box Warning: **WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; AND WITHDRAWAL SYMPTOMS.** The concomitant use of benzodiazepines, including clobazam, and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. The use of benzodiazepines, including clobazam, exposes patients to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing clobazam, assess each patient’s risk for abuse, misuse, and addiction, and monitor all patients regularly for the development of these behaviors or conditions. The continued use of benzodiazepines, including clobazam, may lead to clinically significant physical dependence. The risks of withdrawal symptoms, including seizures, which can be life-threatening, are increased with abrupt discontinuation or rapid dosage reduction of clobazam. In patients using clobazam for a prolonged period, gradually taper the dosage to reduce the risk of withdrawal reactions.
- Several serious warnings are associated with clobazam use due to its pharmacological profile as a benzodiazepine.
- The most critical is the risk of significant central nervous system (CNS) depression, manifesting as profound sedation, somnolence, psychomotor slowing, and cognitive impairment, which can compromise the ability to drive or operate machinery safely.
- Concomitant use with other CNS depressants, particularly opioids, substantially increases the risk of severe sedation, respiratory depression, coma, and death.
- Patients should be warned about the dangers of combining these medications.
- Clobazam carries a risk of physical and psychological dependence, and abrupt discontinuation can precipitate severe withdrawal symptoms, including seizures, psychosis, and status epilepticus.
- Therefore, gradual dose reduction is imperative when discontinuing therapy.
- Like other antiepileptic drugs, clobazam has been associated with an increased risk of suicidal thoughts or behavior; patients and caregivers should be monitored for new or worsening depression, suicidal ideation, or unusual changes in behavior.
- Rare but serious dermatological reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported, requiring immediate discontinuation upon the appearance of rash.
- Patients with severe hepatic or renal impairment require cautious dosing due to altered metabolism and excretion.
How it Works (Mechanism of Action)
Clobazam is classified as a 1,5-benzodiazepine, a unique structural characteristic distinguishing it from conventional 1,4-benzodiazepines. Its primary mechanism of action involves the positive allosteric modulation of gamma-aminobutyric acid (GABA) type A (GABA-A) receptors. GABA is the principal inhibitory neurotransmitter in the central nervous system. By binding to specific benzodiazepine sites on the GABA-A receptor complex, clobazam enhances the inhibitory effects of GABA. This binding facilitates the increased frequency of chloride channel opening, leading to a greater influx of chloride ions into the neuron. The resulting hyperpolarization of the neuronal membrane decreases neuronal excitability and stabilizes the neuronal firing threshold. This enhanced inhibitory neurotransmission contributes to clobazam's anxiolytic, sedative, anticonvulsant, and muscle relaxant properties. In the context of Lennox-Gastaut Syndrome, this mechanism helps to suppress hypersynchronous neuronal activity responsible for seizure generation and propagation, thereby reducing seizure frequency and severity.
Commercial Brands (Alternatives)
No other brands found for this formula.